2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-134912
    CMPPE 841253-81-4 98%
    CMPPE is a GABAB receptor positive allosteric modulator (PAM) that inhibits alcohol self-administration and reinstatement behavior in rats.
    CMPPE
  • HY-134937
    BC8-15 950385-77-0 98%
    BC8-15 is a PDE inhibitor with IC50 values of 0.28, 0.22, and 6.46 µM for inhibiting PDE8A, PDE4A, and PDE7A, respectively. BC8-15 can enhance steroidogenesis in mouse Leydig cells.
    BC8-15
  • HY-135000
    Decarbamoylsaxitoxin 58911-04-9 98%
    Decarbamoylsaxitoxin is an acid hydrolysis product of saxitoxin. Decarbamoylsaxitoxin is a potent neurotoxin that has a lower potency than saxitoxin .
    Decarbamoylsaxitoxin
  • HY-135034
    UMB68 sodium 581099-89-0 98%
    UMB68 sodium is a selective GHB receptor ligand. UMB68 sodium displaces [3H]NCS-382 with an IC50 of 38 nM in rat cerebrocortical membranes. UMB68 sodium has no significant affinity at GABAB receptors, cannot be metabolized to GABA-active compounds.
    UMB68 sodium
  • HY-135131
    Synthalin hydrochloride 301-15-5 98%
    Synthalin hydrochloride is a K+ channel blocker with neuronal excitability modulating activity. Synthalin hydrochloride has an effect on NMDA-mediated depolarization, possibly through receptor-mediated modulation of L-glutamate and serotonin (5-HT). The use of Synthalin hydrochloride can enhance the understanding of changes in membrane potential of different neurons and help study the role of polyamines in neuronal excitability.
    Synthalin hydrochloride
  • HY-135166
    2-(1-Hydroxypentyl)benzoic acid 380905-48-6 98%
    2-(1-Hydroxypentyl)benzoic acid is a compound being explored for its potential use in the treatment of acute ischemic stroke (AIS).
    2-(1-Hydroxypentyl)benzoic acid
  • HY-135167
    HOCPCA 867178-11-8 98%
    HOCPCA is a compound with neuroprotective activity that improves sensorimotor function in mice after experimental stroke. HOCPCA selectively binds to the CaMKIIα hub domain, modulates signaling of different CaMKII pools, and alleviates abnormal CaMKII signaling after cerebral ischemia. HOCPCA promotes hippocampal neuronal activity and enhances working memory. HOCPCA also normalizes Thr286 autophosphorylation in the cytoplasm after ischemia and downregulates ischemia-specific expression of active CaMKII enzymatic cleavage fragments. HOCPCA binds to the GHB binding site with 27-fold higher affinity than GHB and has good blood-brain barrier penetration ability.
    HOCPCA
  • HY-135204
    Deschloronorketamine hydrochloride 7015-20-5 98%
    Deschloronorketamine hydrochloride is an arylcyclohexylamine and is a metabolite of Deschloroketamine.
    Deschloronorketamine hydrochloride
  • HY-135208
    tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate 916048-02-7 98%
    tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate is an intermediate used in the synthesis of potent DP2 receptor antagonists based on a novel spiro-indolinone compound.
    tert-Butyl 2-(5-chloro-2,2'-dioxospiro[indole-3,3'-pyrrolidine]-1-yl)acetate
  • HY-135222
    MMAI hydrochloride 132980-17-7 98%
    MMAI (5-Methoxy-6-methyl-2-aminoindan) hydrochloride is a selective serotonin releaser that does not produce psychoactive or hallucinogenic effects in the context of drug discrimination in rats. MMAI hydrochloride induces a behavioral syndrome in rats, including hypokinesia with freezing, spinning, Straub tail, flat posture, and reduced sleep time.
    MMAI hydrochloride
  • HY-135228
    GZ4 68312-88-9 98%
    GZ4 is a calcium current inhibitor with direct inhibitory activity on cell surface channels. GZ4 inhibition reverses mechanical hyperalgesia/hyperalgesia in a spinal nerve ligation-induced neuropathic pain model. The mechanism of action of GZ4 is similar to that of gabapentin, but the time course of its biological effects is more rapid, indicating that GZ4 can directly inhibit calcium channel currents.
    GZ4
  • HY-135241
    25I-NBF hydrochloride 1539266-13-1 98%
    25I-NBF hydrochloride is a highly potent partial agonist for the 5-HT2A receptors receptor with a Ki value of 0.26 nM and an EC50 value of 1.6 nM.
    25I-NBF hydrochloride
  • HY-135265
    Moclobemide N-Oxide 64544-24-7 98%
    Moclobemide N-Oxide (Ro 12-5637) is N-oxide metabolite of Moclobemide. Moclobemide N-Oxide retains certain MAO-A (monoamine oxidase) inhibitory activity, but is generally present in low concentrations. Moclobemide N-Oxide can be detected by UV absorption at 240 nm.
    Moclobemide N-Oxide
  • HY-135284
    FTY720-Mitoxy 1604816-11-6 98%
    FTY720-Mitoxy is a fingolimod hydrochloride (HY-12005) derivative with neuroprotective and PP2A activating activities. FTY720-Mitoxy has the property of targeting mitochondria. In addition, FTY720-Mitoxy protects neurons by reducing inflammatory responses and is used in the study of neurodegenerative diseases such as Parkinson's disease.
    FTY720-Mitoxy
  • HY-135329
    Solifenacin D5 hydrochloride 1426174-05-1 98%
    Solifenacin D5 hydrochloride is a deuterium labeled Solifenacin hydrochloride. Solifenacin hydrochloride is a muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.
    Solifenacin D5 hydrochloride
  • HY-135387
    4-Desmethyl Istradefylline 160434-48-0 98%
    4-Desmethyl Istradefylline is a metabolite of Istradefylline. 4-Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
    4-Desmethyl Istradefylline
  • HY-135412
    N-Methyl Duloxetine hydrochloride 916135-70-1 98%
    N-Methyl Duloxetine hydrochloride is an analgesic. N-Methyl Duloxetine (hydrochloride) elicits both tonic and use-dependent block of neuronal Na+ channels.
    N-Methyl Duloxetine hydrochloride
  • HY-135456
    Ro4368554 478082-99-4 98%
    Ro4368554 is a brain-penetrant and selective 5-HT6 antagonist that reverses memory deficits induced by scopolamine and tryptophan depletion. Ro4368554 can be utilized in research related to memory deficits.
    Ro4368554
  • HY-135460
    Milameline 139886-32-1 98%
    Milameline is a muscarinic receptor agonist that improves cognition.
    Milameline
  • HY-135464
    (±)-LY367385 198419-90-8 ≥98.0%
    (±)-LY367385 is the racemate of LY367385. LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 μM for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis，compared with > 100 μM for mGlu5a.
    (±)-LY367385
Cat. No. Product Name / Synonyms Application Reactivity